Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis.

ABSTRACT: The prevalence of nonalcoholic fatty liver disease (NAFLD) is rapidly growing throughout the world. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is likely to become the leading cause of cirrhosis and etiology for liver transplantation in future decades in the Western World. Most patients with NAFLD have some components of metabolic syndrome, including obesity, insulin resistance, dyslipidemia, and hypertension. NAFLD encompasses a wide spectrum of liver damage, ranging from simple steatosis to NASH, that can progress to advanced liver disease, as well as hepatocellular carcinoma. Unfortunately, the options for the pharmacological treatment of NASH are still very limited. Nonetheless, several classes of therapies have shown promise, and are currently being evaluated i

SUBMITTER: Sinakos E 

PROVIDER: S-EPMC9062842 | biostudies-literature | 2022 May-Jun

REPOSITORIES: biostudies-literature